BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stockley RA, Turner AM. α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends in Molecular Medicine 2014;20:105-15. [DOI: 10.1016/j.molmed.2013.11.006] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Sapey E, Yonel Z, Edgar R, Parmar S, Hobbins S, Newby P, Crossley D, Usher A, Johnson S, Walton GM, McGuinness A, Chapple I, Stockley R. The clinical and inflammatory relationships between periodontitis and chronic obstructive pulmonary disease. J Clin Periodontol 2020;47:1040-52. [PMID: 32567697 DOI: 10.1111/jcpe.13334] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Cummings EE, O'Reilly LP, King DE, Silverman RM, Miedel MT, Luke CJ, Perlmutter DH, Silverman GA, Pak SC. Deficient and Null Variants of SERPINA1 Are Proteotoxic in a Caenorhabditis elegans Model of α1-Antitrypsin Deficiency. PLoS One 2015;10:e0141542. [PMID: 26512890 DOI: 10.1371/journal.pone.0141542] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
3 Carvalho MOS, Souza ALCS, Carvalho MB, Pacheco APAS, Rocha LC, do Nascimento VML, Figueiredo CVB, Guarda CC, Santiago RP, Adekile A, Goncalves MS. Evaluation of Alpha-1 Antitrypsin Levels and SERPINA1 Gene Polymorphisms in Sickle Cell Disease. Front Immunol 2017;8:1491. [PMID: 29163550 DOI: 10.3389/fimmu.2017.01491] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Chukowry PS, Edgar RG, Turner AM. Alpha 1 antitrypsin deficiency: a rare multisystem disease, predominantly affecting the lung. Expert Opinion on Orphan Drugs 2019;7:315-26. [DOI: 10.1080/21678707.2019.1651640] [Reference Citation Analysis]
5 Turner AM, Tamasi L, Schleich F, Hoxha M, Horvath I, Louis R, Barnes N. Clinically relevant subgroups in COPD and asthma. Eur Respir Rev 2015;24:283-98. [PMID: 26028640 DOI: 10.1183/16000617.00009014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
6 Taggart C, Mall MA, Lalmanach G, Cataldo D, Ludwig A, Janciauskiene S, Heath N, Meiners S, Overall CM, Schultz C, Turk B, Borensztajn KS. Protean proteases: at the cutting edge of lung diseases. Eur Respir J 2017;49:1501200. [PMID: 28179435 DOI: 10.1183/13993003.01200-2015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
7 Sivalingam GN, Cryar A, Williams MA, Gooptu B, Thalassinos K. Deconvolution of ion mobility mass spectrometry arrival time distributions using a genetic algorithm approach: Application to α1-antitrypsin peptide binding. International Journal of Mass Spectrometry 2018;426:29-37. [DOI: 10.1016/j.ijms.2018.01.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
8 Wan T, Ping Y. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders. Adv Drug Deliv Rev 2021;168:196-216. [PMID: 32416111 DOI: 10.1016/j.addr.2020.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
9 Santos G, Turner AM. Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Fac Rev 2020;9:1. [PMID: 33659933 DOI: 10.12703/b/9-1] [Reference Citation Analysis]
10 Feng L, Zhang J, Zhu N, Ding Q, Zhang X, Yu J, Qiang W, Zhang Z, Ma Y, Huang D, Shen Y, Fang S, Yu Y, Wang H, Shen Y. Ubiquitin ligase SYVN1/HRD1 facilitates degradation of the SERPINA1 Z variant/α-1-antitrypsin Z variant via SQSTM1/p62-dependent selective autophagy. Autophagy 2017;13:686-702. [PMID: 28121484 DOI: 10.1080/15548627.2017.1280207] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
11 Guo S, Booten SL, Watt A, Alvarado L, Freier SM, Teckman JH, McCaleb ML, Monia BP. Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease. Rare Dis 2014;2:e28511. [PMID: 25054094 DOI: 10.4161/rdis.28511] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
12 Liu Y, Huang D, Li B, Liu W, Sooranna SR, Pan X, Huang Z, Guo J. Association between α1-antitrypsin and acute coronary syndrome. Exp Ther Med 2020;20:119. [PMID: 33005245 DOI: 10.3892/etm.2020.9247] [Reference Citation Analysis]
13 Viglio S, Bak EG, Schouten IGM, Iadarola P, Stolk J. Protease-Specific Biomarkers to Analyse Protease Inhibitors for Emphysema Associated with Alpha 1-Antitrypsin Deficiency. An Overview of Current Approaches. Int J Mol Sci 2021;22:1065. [PMID: 33494436 DOI: 10.3390/ijms22031065] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Silberstein DZ, Karuppanan K, Aung HH, Chen CH, Cross CE, McDonald KA. An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana. Free Radic Biol Med 2018;120:303-10. [PMID: 29551638 DOI: 10.1016/j.freeradbiomed.2018.03.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kalfopoulos M, Wetmore K, ElMallah MK. Pathophysiology of Alpha-1 Antitrypsin Lung Disease. Methods Mol Biol. 2017;1639:9-19. [PMID: 28752442 DOI: 10.1007/978-1-4939-7163-3_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
16 Townsend SA, Edgar RG, Ellis PR, Kantas D, Newsome PN, Turner AM. Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease. Aliment Pharmacol Ther. 2018;47:877-885. [PMID: 29446109 DOI: 10.1111/apt.14537] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
17 Dau T, Edeleva EV, Seidel SA, Stockley RA, Braun D, Jenne DE. Quantitative analysis of protease recognition by inhibitors in plasma using microscale thermophoresis. Sci Rep 2016;6:35413. [PMID: 27739542 DOI: 10.1038/srep35413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Assaf S, Hanania NA. Novel therapeutic targets and drug development for the precision treatment of COPD. Expert Review of Precision Medicine and Drug Development 2019;4:121-8. [DOI: 10.1080/23808993.2019.1614438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Balbi B, Sangiorgi C, Gnemmi I, Ferrarotti I, Vallese D, Paracchini E, Delle Donne L, Corda L, Baderna P, Corsico A, Carone M, Brun P, Cappello F, Ricciardolo FL, Ruggeri P, Mumby S, Adcock IM, Caramori G, Di Stefano A. Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD. Int J Chron Obstruct Pulmon Dis 2019;14:1879-93. [PMID: 31686800 DOI: 10.2147/COPD.S207203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Milstein S, Qian K, Zhang L, Sehgal A. Methods to Identify and Characterize siRNAs Targeting Serpin A1 In Vitro and In Vivo Using RNA Interference. Methods Mol Biol 2017;1639:115-26. [PMID: 28752451 DOI: 10.1007/978-1-4939-7163-3_11] [Reference Citation Analysis]
21 Henao MP, Craig TJ. Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency. Expert Rev Respir Med 2016;10:1281-94. [PMID: 27771979 DOI: 10.1080/17476348.2016.1249851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Wang N, Wang Q, Du T, Gabriel ANA, Wang X, Sun L, Li X, Xu K, Jiang X, Zhang Y. The Potential Roles of Exosomes in Chronic Obstructive Pulmonary Disease. Front Med (Lausanne) 2020;7:618506. [PMID: 33521025 DOI: 10.3389/fmed.2020.618506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Zhou T, Huang Z, Zhu X, Sun X, Liu Y, Cheng B, Li M, Liu Y, He C, Liu X. Alpha-1 Antitrypsin Attenuates M1 Microglia-Mediated Neuroinflammation in Retinal Degeneration. Front Immunol 2018;9:1202. [PMID: 29899745 DOI: 10.3389/fimmu.2018.01202] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
24 Edgar RG, Patel M, Bayliss S, Crossley D, Sapey E, Turner AM. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. Int J Chron Obstruct Pulmon Dis 2017;12:1295-308. [PMID: 28496314 DOI: 10.2147/COPD.S130440] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 6.6] [Reference Citation Analysis]
25 Van Leeuw JB, Berra E, Gu Y, Petit T, Lacroix V, Lanthier N, Van Hoof M, Staessen JA, Persu A. Alpha-1 antitrypsin deficiency: a novel cause of isolated systolic resistant hypertension? J Hypertens 2016;34:1659-61. [PMID: 27270187 DOI: 10.1097/HJH.0000000000000997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015;385:1789-1798. [PMID: 25943943 DOI: 10.1016/s0140-6736(15)60693-6] [Cited by in Crossref: 147] [Cited by in F6Publishing: 62] [Article Influence: 21.0] [Reference Citation Analysis]
27 Kim N, Duncan GA, Hanes J, Suk JS. Barriers to inhaled gene therapy of obstructive lung diseases: A review. J Control Release 2016;240:465-88. [PMID: 27196742 DOI: 10.1016/j.jconrel.2016.05.031] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
28 Fazleen A, Wilkinson T. The emerging role of proteases in α1-antitrypsin deficiency and beyond. ERJ Open Res 2021;7:00494-2021. [PMID: 34820446 DOI: 10.1183/23120541.00494-2021] [Reference Citation Analysis]
29 Hogan PE, Koelsch T, Daley CL, Kasperbauer SH. A Woman with a 15-Year History of Bronchiectasis and Recurrent Nontuberculous Mycobacterium Pulmonary Disease. Ann Am Thorac Soc 2018;15:380-2. [PMID: 29493335 DOI: 10.1513/AnnalsATS.201707-585CC] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Xu X, Huang K, Dong F, Qumu S, Zhao Q, Niu H, Ren X, Gu X, Yu T, Pan L, Yang T, Wang C. The Heterogeneity of Inflammatory Response and Emphysema in Chronic Obstructive Pulmonary Disease. Front Physiol 2021;12:783396. [PMID: 34950055 DOI: 10.3389/fphys.2021.783396] [Reference Citation Analysis]
31 Gaczynska M, Karpowicz P, Stuart CE, Norton MG, Teckman JH, Marszal E, Osmulski PA. AFM Imaging Reveals Topographic Diversity of Wild Type and Z Variant Polymers of Human α1-Proteinase Inhibitor. PLoS One 2016;11:e0151902. [PMID: 27008547 DOI: 10.1371/journal.pone.0151902] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
32 Craig TJ, Henao MP. Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder. Allergy 2018;73:2110-21. [PMID: 29984428 DOI: 10.1111/all.13558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chiuchiolo MJ, Crystal RG. Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease. Ann Am Thorac Soc 2016;13 Suppl 4:S352-69. [PMID: 27564673 DOI: 10.1513/AnnalsATS.201506-344KV] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
34 Nyon MP, Prentice T, Day J, Kirkpatrick J, Sivalingam GN, Levy G, Haq I, Irving JA, Lomas DA, Christodoulou J, Gooptu B, Thalassinos K. An integrative approach combining ion mobility mass spectrometry, X-ray crystallography, and nuclear magnetic resonance spectroscopy to study the conformational dynamics of α1 -antitrypsin upon ligand binding. Protein Sci 2015;24:1301-12. [PMID: 26011795 DOI: 10.1002/pro.2706] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
35 Low EV, Hughes SM, Zaffarullah S, Kantas D, Stockley RA, Turner AM. ICS Use May Modify FEV1 Decline in α1-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils. Respiration 2018;95:114-21. [PMID: 29253843 DOI: 10.1159/000481867] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
36 Cathomas M, Schüller A, Candinas D, Inglin R. Severe postoperative wound healing disturbance in a patient with alpha-1-antitrypsin deficiency: the impact of augmentation therapy. Int Wound J 2015;12:601-4. [PMID: 25818083 DOI: 10.1111/iwj.12419] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
37 Van Scherpenzeel M, Willems E, Lefeber DJ. Clinical diagnostics and therapy monitoring in the congenital disorders of glycosylation. Glycoconj J 2016;33:345-58. [PMID: 26739145 DOI: 10.1007/s10719-015-9639-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
38 Khodayari N, Wang RL, Oshins R, Lu Y, Millett M, Aranyos AM, Mostofizadeh S, Scindia Y, Flagg TO, Brantly M. The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease. IJMS 2021;22:13255. [DOI: 10.3390/ijms222413255] [Reference Citation Analysis]
39 Pye A, Turner AM. Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. Expert Opin Investig Drugs 2019;28:891-902. [PMID: 31550938 DOI: 10.1080/13543784.2019.1672656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
40 Hadzik-Blaszczyk M, Zdral A, Zielonka TM, Rozy A, Krupa R, Falkowski A, Wardyn KA, Chorostowska-Wynimko J, Zycinska K. SERPINA1 Gene Variants in Granulomatosis with Polyangiitis. Adv Exp Med Biol 2018;1070:9-18. [PMID: 29460271 DOI: 10.1007/5584_2018_156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
41 Craig TJ. Suspecting and Testing for Alpha-1 Antitrypsin Deficiency-An Allergist's and/or Immunologist's Perspective. J Allergy Clin Immunol Pract 2015;3:506-11. [PMID: 26032475 DOI: 10.1016/j.jaip.2015.04.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
42 Green C, Parr D, Edgar R, Stockley R, Turner A. Lung density associates with survival in alpha 1 antitrypsin deficient patients. Respiratory Medicine 2016;112:81-7. [DOI: 10.1016/j.rmed.2016.01.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
43 Wezynfeld NE, Bonna A, Bal W, Frączyk T. Ni( ii ) ions cleave and inactivate human alpha-1 antitrypsin hydrolytically, implicating nickel exposure as a contributing factor in pathologies related to antitrypsin deficiency. Metallomics 2015;7:596-604. [DOI: 10.1039/c4mt00316k] [Cited by in Crossref: 9] [Article Influence: 1.3] [Reference Citation Analysis]
44 Ma S, Lin YY, Cantor JO, Chapman KR, Sandhaus RA, Fries M, Edelman JM, McElvaney G, Turino GM. The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials. Chronic Obstr Pulm Dis 2016;4:34-44. [PMID: 28848909 DOI: 10.15326/jcopdf.4.1.2016.0156] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
45 Turner AM, Stolk J, Bals R, Lickliter JD, Hamilton J, Christianson DR, Given BD, Burdon JG, Loomba R, Stoller JK, Teckman JH. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. J Hepatol 2018;69:378-84. [PMID: 29572094 DOI: 10.1016/j.jhep.2018.03.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
46 Rangaraju M, Turner AM. Why is Disease Penetration so Variable in Alpha-1 Antitrypsin Deficiency? The Contribution of Environmental Factors. Chronic Obstr Pulm Dis 2020;7:280-9. [PMID: 32698254 DOI: 10.15326/jcopdf.7.3.2019.0177] [Reference Citation Analysis]
47 Sabbagh DK, Barmayehvar B, Nguyen T, Edgar RG, Turner AM. Managing panniculitis in alpha-1 antitrypsin deficiency: Systematic review of evidence behind treatment. World J Dermatol 2018; 7(1): 1-8 [DOI: 10.5314/wjd.v7.i1.1] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
48 Santos GF, Ellis P, Farrugia D, Turner AM. Nephrotic syndrome secondary to alpha-1 antitrypsin deficiency. BMJ Case Rep 2021;14:e240288. [PMID: 33674298 DOI: 10.1136/bcr-2020-240288] [Reference Citation Analysis]
49 Zhang Y, Davis DA, AboulFotouh K, Wang J, Williams D, Bhambhani A, Zakrewsky M, Maniruzzaman M, Cui Z, Williams RO 3rd. Novel formulations and drug delivery systems to administer biological solids. Adv Drug Deliv Rev 2021;172:183-210. [PMID: 33705873 DOI: 10.1016/j.addr.2021.02.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Teschler H. Long-term experience in the treatment of α1-antitrypsin deficiency: 25 years of augmentation therapy. Eur Respir Rev 2015;24:46-51. [PMID: 25726554 DOI: 10.1183/09059180.10010714] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
51 Wahlund CJE, Eklund A, Grunewald J, Gabrielsson S. Pulmonary Extracellular Vesicles as Mediators of Local and Systemic Inflammation. Front Cell Dev Biol 2017;5:39. [PMID: 28491866 DOI: 10.3389/fcell.2017.00039] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
52 Jasper AE, McIver WJ, Sapey E, Walton GM. Understanding the role of neutrophils in chronic inflammatory airway disease. F1000Res 2019;8:F1000 Faculty Rev-557. [PMID: 31069060 DOI: 10.12688/f1000research.18411.1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]